Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study

References

• Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. doi:10.1186/1741-7015-11-181
   PubMed Web of Science ®Google Scholar
• Mayhew D, Devos N, Lambert C, et al.; on behalf of the AERIS Study Group. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 73;2018:422–430. doi:10.1136/thoraxjnl-2017-210408
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Mackay AJ, Singh R. COPD exacerbations: impact and prevention. Breathe. 2013;9:434–440. doi:10.1183/20734735.002913
   Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al.; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Toraldo DM, Conte L. Influence of the lung microbiota dysbiosis in chronic obstructive pulmonary disease exacerbations: the controversial use of corticosteroid and antibiotic treatments and the role of eosinophils as a disease marker. J Clin Med Res. 2019;11:667–675. doi:10.14740/jocmr3875
   PubMedGoogle Scholar
• Agustí A, Calverley PM, Decramer M, Stockley RA, Wedzicha JA. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. Chronic Obstr Pulm Dis. 2014;1:166–184. doi:10.15326/jcopdf.1.2.2014.0134
   PubMedGoogle Scholar
• Aisanov Z, Bai C, Bauerle O, et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis. 2012;7:271–282. doi:10.2147/COPD.S28059
   PubMed Web of Science ®Google Scholar
• Davis KJ, Landis SH, Oh YM, et al. Continuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis. 2014;10:39–55. doi:10.2147/COPD.S70162
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613. doi:10.1164/ajrccm.161.5.9908022
   PubMed Web of Science ®Google Scholar
• Down K, Amour A, Baldwin IR, et al. Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase for the treatment of respiratory disease. J Med Chem. 2015;58:7381–7399. doi:10.1021/acs.jmedchem.5b00767
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ Inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77. doi:10.1016/j.pupt.2017.08.008
   PubMed Web of Science ®Google Scholar
• Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134:314–322. doi:10.1016/j.jaci.2014.02.001
   PubMed Web of Science ®Google Scholar
• To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:897–904. doi:10.1164/rccm.200906-0937OC
   PubMed Web of Science ®Google Scholar
• Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342:866–871. doi:10.1126/science.1243292
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. AM J Respir Crit Care Med. 2011;183:1176–1186. doi:10.1164/rccm.201008-1285OC
   PubMed Web of Science ®Google Scholar
• McKendry RT, Spalluto CM, Burke H, et al. Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 axis. Am J Respir Crit Care Med. 2016;193:642–651. doi:10.1164/rccm.201504-0782OC
   PubMed Web of Science ®Google Scholar
• Stark AK, Chandra A, Chakraborty K, et al. PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat Commun. 2018;9:3174. doi:10.1038/s41467-018-05674-8
   PubMed Web of Science ®Google Scholar
•  Cahn A, Hamblin JN, Robertson J, et al. An Inhaled PI3Kδ inhibitor improves recovery in acutely exacerbating COPD patients, a randomized trial. Int J Chron Obstruct Pulmon Dis. In press 2021.
   Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS task force: standardisation of spirometry. Eur Respir J. 2005;26:319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183:323–329. doi:10.1164/rccm.201005-0762OC
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George respiratory questionnaire. Chest. 2007;132:456–463. doi:10.1378/chest.06-0702
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Beck B, Clerisme-Beaty E, et al. Recruiting patients after hospital discharge for acute exacerbation of COPD: challenges and lessons learned. Chronic Obstr Pulm Dis. 2017;4:265–278. doi:10.15326/jcopdf.4.4.2016.0176
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75(6):520–527. doi:10.1136/thoraxjnl-2019-214484
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• Ni W, Bao J, Yang D, et al. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. Infect Dis. 2019;51:639–650. doi:10.1080/23744235.2019.1644456
   PubMed Web of Science ®Google Scholar
• Wilson R, Jarvis E, Montembault M, Hamblin JN, Hessel EM, Cahn A. Safety, tolerability, and pharmacokinetics of single and repeat doses of nemiralisib administered via the Ellipta dry powder inhaler to healthy subjects. Clin Ther. 2018;40:1410–1417. doi:10.1016/j.clinthera.2018.06.011
   PubMed Web of Science ®Google Scholar
• Wilson R, Templeton A, Leemereise C, et al. Safety, tolerability, and pharmacokinetics of a new formulation of nemiralisib administered via a dry powder inhaler to healthy individuals. Clin Ther. 2019;41:1214–1220. doi:10.1016/j.clinthera.2019.04.008
   PubMed Web of Science ®Google Scholar
• Chang JE, Kahl BS. PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014;9:33–43. doi:10.1007/s11899-013-0189-7
   PubMed Web of Science ®Google Scholar